Kyverna Therapeutics Inc. presented new clinical data highlighting the performance of its CAR T cell therapy, Miv-cel (KYV-101), in patients with stiff person syndrome (SPS). The company reported statistically significant improvements across all primary and secondary endpoints in the KYSA-8 registrational trial, including the Timed 25-Foot Walk, Modified Rankin Scale, Distribution of Stiffness Index, Hauser Ambulation Index, and Heightened Sensitivity Scale. The therapy demonstrated a 100% elimination of off-label immunotherapies with a single dose and was described as well-tolerated with a manageable safety profile. The trial results establish a clear regulatory path for a Biologics License Application filing in the first half of 2026, with the company positioned to be first-to-market in SPS and plans to follow with myasthenia gravis. Kyverna also noted strengthened financial resources with a cash runway into 2028. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.